Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The KIT D816V mutant is a constitutively active form of the receptor tyrosine kinase involved primarily in driving clonal expansion and accumulation of neoplastic mast cells. Its detection has major diagnostic, prognostic, and therapeutic implications—especially regarding resistance to imatinib—and requires sensitive molecular assays due to often low abundance within patient samples.
Inhibition of tyrosine kinase activity (though often with resistance in the case of D816V)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KIT D816V Mutant (KIT D816V).